To achieve viral reservoir reductions in patients it may be important to perform trials in subjects with potent HIV-specific CD8+ T-cell responses against non-escaped epitopes, for example, in subjects treated early post-infection and for a limited duration[54], or in combination with therapeutic vaccination. The gene discussed is CD8A; the disease is infection.